Methotrexate‐Induced Chronic Liver Injury: Guidelines for Detection and Prevention

The American Journal of Gastroenterology

Volumn 83, Issue 12, 1988, Pages 1337-1345

  Schiff, Eugene ^b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

CANCER; HISTOLOGY; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

CHRONIC DISEASE; HUMAN; LIVER DISEASES; METHOTREXATE; PROGNOSIS;

EID: 0024215853     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1988.tb02265.x     Document Type: Article

References (82)

1. Analogs of pteroylglutamic acid. IIL 4–amino derivatives
2. Antagonist for pteroylglutamic acid
3. Temporary remissions in acute leukemia in children produced by folic antagonist 4–amithopteroylglutamic acid (aminopterin)
4. Therapeutic suppression of tissue reactivity. IL Effect of aminopterin in rheumatoid arthritis and psoriasis
5. The pharmacology and clinical use of methotrexate
6. Historical perspective on the use of methotrexate for the treatment of rheumatoid arthritis
7. Methotrexate in the treatment of arthritis and connective tissue diseases
8. The clinical pharmacology of methotrexate: A new application of an old drug
9. The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritis
10. Methotrexate therapy in rheumatoid arthritis. Current status
11. Methodrexate
12. Methotrexate: Mechanism of action on DNA synthesis in psoriasis
13. Methotrexate in the treatment of psoriasis: A controlled clinical trial
14. Methotrexate for psoriasis
15. Parenteral methotrexate in psoriasis
16. Methotrexate for psoriasis. A new therapeutic schedule
17. Methotrexate and the liver
18. Methotrexate and the liver
19. Low incidence of hepatotoxicity associated with long‐term low‐dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio
20. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment
21. Hepatotoxic effects of oncotherapeutic agents
22. Antineoplastic agents and the liver
23. Methotrexate hepatotoxicity in cirrhosis. Consideration of liver biopsies at regular intervals
24. Hepatotoxicity
25. Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonist
26. Hepatic fibrosis in children with acute leukemia
27. Liver disease associated with methotrexate treatment of psoriatic patients
28. Methotrexate‐induced hepatic injury in an adult
29. Hepatotoxic effects of methotrexate
30. Cirrhosis associated with methotrexate treatment of psoriasis
31. Cirrhosis caused by methotrexate in the treatment of psoriasis
32. Cirrhosis following methotrexate administration for psoriasis
33. Structural and functional abnormalities of the liver in cirrhosis. Before and during methotrexate therapy
34. Evaluation of possible chronic hepatotoxicity from methotrexate for cirrhosis
35. Liver biopsies for psoriatics related to methotrexate therapy. 2. Findings before and after methotrexate therapy in 88 patients. A blind study
36. Methotrexate guidelines; Revised
37. Psoriasis‐liver‐methotrexate interactions. Cooperative study
38. A prospective study of the effects of weekly oral methotrexate on liver biopsy. Findings in severe psoriasis
39. Liver biopsies from psoriatics related to methotrexate therapy
40. Methotrexate treatment of rheumatoid arthritis
41. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy and safety
42. Liver biopsies from psoriatics related to methotrexate therapy
43. Liver biopsy in psoriasis. A controlled study
44. Liver biopsy in methotrex‐ate‐treated psoriatics: A re‐evaluation
45. Parenteral methotrexate for psoriasis
46. Liver damage due to methotrexate in patients with psoriasis
47. Methotrexate hepato‐toxicity in psoriasis: Comparison of different dose regimens
48. Studies on the frequency and pathogenesis of liver involvement in rheumatoid arthritis
49. IIL The liver in rheumatic diseases
50. Clinical associations between arthritis and liver disease
51. Liver biopsy findings in patients with rheumatoid and psoriatic arthritis on long‐term treatment with methotrexate
52. Low‐dose methotrexate treatment of rheumatoid arthritis. Long‐term observations
53. Hepatic histology following prolonged treatment of rheumatoid arthritis with bolus methotrexate
54. A long‐term prospective study of methotrexate in rheumatoid arthritis
55. Liver histology in rheumatoid arthritis before and after prolonged methotrexate therapy
56. Methotrexate in rheumatoid arthritis; a longitudinal study of liver biopsies
57. Hepatoxicity of prolonged methotrexate therapy for rheumatoid arthritis
58. Liver injury associated with methotrexate therapy for psoriasis
59. Hepatotoxicity after long‐term methotrexate therapy
60. Morphogenesis of fibrosis and cirrhosis in methotrexate‐treated patients with psoriasis
61. Studies on the folic acid vitamins: IV. The persistence of amethopterin in mammalian tissues
62. The relation of folic acid reductase to aminopterin toxicity
63. Hepatoxicity of methotrexate in the treatment of psoriasis
64. Liver biopsy in psoriatics previously treated with potassium amsenite
65. Hepatotoxicity of long‐term methotrexate therapy for psoriasis
66. HLA antigens in methotrexate‐induced liver disease
67. Predictive value of HLA antigen for methotrexate‐induced liver damage in patients with psoriasis
68. Efficacy of low‐dose methotrexate in rheumatoid arthritis
69. Alteration of methotrexate toxicity in rats by manipulation of dietary components
70. Ultrasound as a screening procedure for methotrexate‐induced hepatic damage in severe psoriasis
71. A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long‐term methotrexate therapy
72. Liver biopsies v. liver scans in methotrexate‐treated patients with psoriasis
73. The aminopyrine breath test, an inadequate early indicator of methotrexate‐induced liver disease in patients with psoriasis
74. Lack of methotrexate hepatotoxicity in rheumatoid arthritis
75. Changes in liver histology during methotrexate therapy of psoriasis correlated to the concentration of methotrexate and folate in erythrocytes
76. Methotrexate‐induced hepatitis in childhood leukemia
77. Interaction of methotrexate with lypotropic factors in rat liver
78. Chronic toxicity of methotrexate in rats: partial to complete protection of the liver by choline
79. Effect of methotrexate therapy in psoriatics on the Ito cells in liver biopsies, assessed by point‐counting
80. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates
81. American College of Physicians. Methotrexate in rheumatoid arthritis